Evans John M., CEO of Beam Therapeutics Inc. ($BEAM), sold shares on the open market seven times in the last 365 days, totaling $3.2 million. His most recent sale occurred on January 30, 2026. These sales rank 2,589th among 11,678 insiders in the database, where the average is $8.6 million across about 6.4 transactions per insider. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 25000 | $0.67 | 1,114,667.0000 | 102,570,801 | 2.29% | 0.02% |
| March 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 25000 | $22.37 | 1,089,667.0000 | 102,570,801 | 2.24% | 0.02% |
| March 31, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 18,672.0000 | 102,570,801 | 57.24% | 0.02% |
| March 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 43,672.0000 | 102,570,801 | 36.40% | 0.02% |
| March 31, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Common Stock | 90000 | $0.00 | 1,179,667.0000 | 102,570,801 | 8.26% | 0.09% |
| March 31, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 25000 | $22.76 | 1,089,667.0000 | 102,570,801 | 2.24% | 0.02% |
| March 31, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 25000 | $0.67 | 1,114,667.0000 | 102,570,801 | 2.29% | 0.02% |
| Jan. 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 22094 | $28.27 | 1,092,573.0000 | 102,570,801 | 1.98% | 0.02% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 5664 | $0.00 | 93,672.0000 | 102,570,801 | 5.70% | 0.01% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 19336 | $0.00 | 0.0000 | 102,570,801 | 100.00% | 0.02% |
| Jan. 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 2906 | $29.00 | 1,089,667.0000 | 102,570,801 | 0.27% | 0.00% |
| Jan. 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 68,672.0000 | 102,570,801 | 26.69% | 0.02% |
| Jan. 30, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 25000 | $0.67 | 1,114,667.0000 | 102,570,801 | 2.29% | 0.02% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 8667 | $29.74 | 1,089,667.0000 | 102,570,801 | 0.79% | 0.01% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 16333 | $29.19 | 1,098,334.0000 | 102,570,801 | 1.47% | 0.02% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 5664 | $0.67 | 1,114,667.0000 | 102,570,801 | 0.51% | 0.01% |
| Jan. 29, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 19336 | $0.67 | 1,109,003.0000 | 102,570,801 | 1.77% | 0.02% |
| Jan. 31, 2026 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 180000 | $0.00 | 180,000.0000 | 102,570,801 | 9999.99% | 0.18% |
| Oct. 2, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 19,336.0000 | 102,570,801 | 56.39% | 0.02% |
| Oct. 1, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 25000 | $0.67 | 1,114,667.0000 | 102,570,801 | 2.29% | 0.02% |
| Oct. 1, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 25000 | $24.51 | 1,089,667.0000 | 102,570,801 | 2.24% | 0.02% |
| Oct. 2, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 25000 | $0.67 | 1,114,667.0000 | 102,570,801 | 2.29% | 0.02% |
| Oct. 2, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 25000 | $24.63 | 1,089,667.0000 | 102,570,801 | 2.24% | 0.02% |
| Oct. 1, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 25000 | $0.00 | 44,336.0000 | 102,570,801 | 36.06% | 0.02% |
| April 1, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 30663 | $18.35 | 1,089,249.0000 | 82,313,008 | 2.74% | 0.04% |
| Jan. 30, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 30000 | $0.67 | 968,659.0000 | 82,313,008 | 3.20% | 0.04% |
| March 31, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Common Stock | 77500 | $0.00 | 1,119,159.0000 | 82,313,008 | 7.44% | 0.09% |
| Jan. 30, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 30000 | $0.00 | 69,336.0000 | 82,313,008 | 30.20% | 0.04% |
| Jan. 31, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 155000 | $0.00 | 155,000.0000 | 82,313,008 | 9999.99% | 0.19% |
| Jan. 30, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 200 | $27.28 | 1,011,659.0000 | 82,313,008 | 0.02% | 0.00% |
| Jan. 30, 2025 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 29800 | $26.75 | 1,011,859.0000 | 82,313,008 | 2.86% | 0.04% |
| Sept. 30, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 60000 | $24.60 | 1,041,659.0000 | 77,151,771 | 5.45% | 0.08% |
| June 27, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 60000 | $24.50 | 1,101,343.0000 | 77,151,771 | 5.17% | 0.08% |
| April 1, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 18102 | $32.13 | 1,161,343.0000 | 77,151,771 | 1.53% | 0.02% |
| April 3, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 53965 | $0.00 | 53,965.0000 | 77,151,771 | 9999.99% | 0.07% |
| April 3, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 99336 | $0.00 | 99,336.0000 | 77,151,771 | 9999.99% | 0.13% |
| March 28, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 60000 | $33.86 | 1,101,262.0000 | 77,151,771 | 5.17% | 0.08% |
| March 31, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Common Stock | 77500 | $0.00 | 1,179,445.0000 | 77,151,771 | 7.03% | 0.10% |
| Jan. 31, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 60000 | $25.33 | 1,161,262.0000 | 77,151,771 | 4.91% | 0.08% |
| Jan. 31, 2024 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 155000 | $24.40 | 155,000.0000 | 77,151,771 | 9999.99% | 0.20% |
| April 3, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 5161 | $30.31 | 1,227,472.0000 | 70,015,305 | 0.42% | 0.01% |
| April 4, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | S | Common Stock | 6493 | $29.09 | 1,220,979.0000 | 70,015,305 | 0.53% | 0.01% |
| Jan. 31, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Stock Option (Right to Buy) | 112500 | $0.00 | 112,500.0000 | 70,015,305 | 9999.99% | 0.16% |
| March 31, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Stock Option (Right to Buy) | 13850 | $0.00 | 196,904.0000 | 70,015,305 | 6.57% | 0.02% |
| March 6, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | L | Common Stock | 225 | $0.00 | 1,162,053.0000 | 70,015,305 | 0.02% | 0.00% |
| March 31, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | A | Common Stock | 56250 | $0.00 | 1,218,303.0000 | 70,015,305 | 4.84% | 0.08% |
| March 31, 2023 | Beam Therapeutics Inc. | $BEAM | Evans John M. | CEO | M | Common Stock | 13850 | $7.22 | 1,232,153.0000 | 70,015,305 | 1.14% | 0.02% |